• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

2025 AGM Information

Notice of Annual General Meeting

This is a notice regarding the International Alliance of ALS/MND Associations’ Annual General Meeting (AGM), taking place virtually via Zoom and in person at the Sheraton Toronto Airport Hotel & Conference Centre, 801 Dixon Road, Toronto, Ontario, Canada.

Date: Saturday, November 29, 2025
Time: 7:00–8:30 am EST 
Zoom link: https://us02web.zoom.us/j/6212859565?omn=81799817727

Thank you to our members who submitted agenda items or resolutions. The submission period is now closed.

Thank you to our members who submitted a nomination for the Board of Directors. Nominations are now closed.

Meeting Materials

  • 2025 AGM Agenda
  • 2024 AGM Minutes
  • Year-end Financial Statements
  • 2024-2025 Annual Report

A resolution to increase membership fees will be presented, as outlined below. 

Background

The membership fee has not increased since 2014. A review of the fee structure was informed by data including the International Monetary Fund cumulative global inflation rate.

It was determined during the review that the World Bank income-based classification system be applied to membership fee calculations. The World Bank uses this system to categorize countries’ economies. This system divides the world’s economies into four groups: low-income, lower-middle-income, upper-middle-income, and high-income. These classifications are updated annually on July 1, based on the Gross National Income per capita of the previous calendar year.

RESOLUTION: That the Alliance membership fees for 2026-2027 be increased as outlined below:

  • The calculation of membership fees to remain at 0.2% of member organization revenue for the previous year.
  • The minimum fee for Full Members to be £125, and then adjusted for inflation each year thereafter by equivalent to the global inflation rate.
  • The fee cap for Full Members to be £12,500, and then adjusted for inflation each year thereafter by equivalent to the global inflation rate.
  • Any Full Member in countries in the lowest income tier as defined by the World Bank income-based classification system may apply to be granted a fee waiver.
  • Any Full Member in the lower-middle-income tier as defined by the World Bank be granted 50% fee relief if they apply for it.
  • For Affiliate Membership categories, the following membership fees proposed to apply for 2026-2027:
    • Emerging Associations: 0.2% of member organization revenue for the previous year if available, and may apply for a membership fee waiver.
    • Network: 0.1% of revenue for the previous year. Less developed networks may apply to be granted a fee waiver.
    • Education and Research: 0.2% if have own revenue, or minimum fee of £125 if have no direct income given operate within a non-profit entity such as a university.
    • Fiscal Sponsorship/Hosting Arrangement: minimum fee of £125.

Voting

Voting will be conducted by a show of hands from in-person and virtual participants at the meeting. 

Members will vote on the following items: 

  • Approval of 2024 AGM Minutes
  • Appointment of new Trustees
  • Receipt of the 2024-2025 accounts
  • Appointment of an Independent Examiner
  • Fixing of the annual subscriptions

Questions

The Alliance welcomes your questions in advance of the AGM. Please send them to cathy.cummings@als-mnd.org. You will also have the opportunity to ask questions during the AGM. 

Proxy Vote Instructions & Form

  1. As a member of the Charity, you are entitled to appoint a proxy to exercise all or any of your rights to attend, speak, and vote at the meeting.
  2. You can only appoint a proxy using the procedures set out in these notes.
  3. A proxy must be an authorized representative of the member (no other individuals are permitted to be proxies) and must attend the meeting to represent you.
  4. If no voting indication is given, your proxy will vote or abstain from voting on the resolutions put to the meeting at their discretion.
  5. Unless the proxy appointment indicates otherwise, it will be treated as:
    • allowing your proxy to vote (or abstain from voting) as they see fit in relation to the limited range of additional resolutions which may be put before the meeting; and
    • appointing your proxy in relation to any adjournment of the meeting.
  6. Proxy appointments must be made using the form below or in writing and emailed to the Secretary of the Charity, Catherine Cummings, at cathy.cummings@als-mnd.org.
  7. The proxy appointments must be notified to the Secretary of the Charity before the commencement of the meeting.
  8. If you are completing the proxy appointment under the authority of a power of attorney or any other authority, you must send the relevant document or a certified copy to the Secretary of the Charity when you return the proxy appointment.
  9. If you wish to change your proxy instructions, you may submit another appointment in the way indicated above. The appointment received last before the latest time for the receipt of proxies will take precedence.
  10. If you wish to revoke your proxy instructions, you may send a notice to the Secretary of the Charity in any of the ways described at note 6 above clearly stating that the instructions are revoked. The revocation must be received by the Secretary of the Charity no later than the commencement of the meeting.
  11. Appointment of a proxy does not preclude you from attending the meeting and voting yourself. If you have appointed a proxy and you attend the meeting and cast a vote yourself, your proxy is no longer entitled to vote on your behalf.
  12. You may only communicate with the Charity about the meeting and appointing a proxy for the meeting using the addresses at note 6. No other methods of communication will be accepted.

2025 Proxy Form

As a member of the Charity, you are entitled to appoint a proxy through this form to exercise all or any of your rights to attend, speak and vote at the meeting.

This field is hidden when viewing the form

2025 Proxy Form

It is the responsibility of the member to determine whether the person to whom they assign the proxy is able and agrees to act in the manner described. Please ensure submission of the completed proxy to the International Alliance of ALS/MND Associations no later than November 23, 2025, at 5:00 pm ET.
Your Name(Required)
I, a voting member in good standing of the International Alliance of ALS/MND Associations, hereby appoint the following person as my proxy to attend, act, and vote on my behalf at the Annual General Meeting of members to be held in person at the Sheraton Toronto Airport Hotel & Conference Centre, 801 Dixon Road, Toronto, Ontario Canada and virtually on November 29, 2025, at 7:00 am ET (including adjournments thereof).(Required)
Failing the person named above, I hereby give my proxy to the following person.(Required)
OR (complete only if you wish to name someone other than the above as your proxy) I hereby appoint the following person, a voting member in good standing, as my proxy to attend, act, and vote on my behalf at the Annual General Meeting of members to be held in person at the Sheraton Toronto Airport Hotel & Conference Centre, 801 Dixon Road, Toronto, Ontario Canada and virtually on November 29, 2025, at 7:00 am ET (including adjournments thereof).
By completing the following boxes, the signing party listed below digitally confirms the proxy appointment.

Primary Sidebar

  • Dick Dayton, USA

    Dick Dayton, USA

  • Norm MacIsaac,  ALS Society of Canada,  ALS Society of Quebec,  Diagnosed 2014

    Norm MacIsaac, ALS Society of Canada, ALS Society of Quebec, Diagnosed 2014

  • Daniel Hare

    Daniel Hare

  • Antonio Ventriglia,  ALS Liga Belgium,  Diagnosed 2013

    Antonio Ventriglia, ALS Liga Belgium, Diagnosed 2013

  • Andrea Zicchieri, Associazione conSLAncio Onlus, Italy

    Andrea Zicchieri, Associazione conSLAncio Onlus, Italy
    AndreaZicchieri_conSLAncioItaly

  • Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

    Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

  • Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

    Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

  • Phil Rossall, MND-Association, UK

    Phil Rossall, MND-Association, UK

  • Francisco Perez Palop, Diagnosed 2013 , FUNDELA, Spain

    Francisco Perez Palop, Diagnosed 2013 , FUNDELA, Spain

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Timothy Holman, Switzerland

    Timothy Holman, Switzerland

  • David Solomon, Diagnosed 2015, MND Association of England, Wales and N Ireland

    David Solomon, Diagnosed 2015, MND Association of England, Wales and N Ireland

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Juvenal Bayona Romero

    Juvenal Bayona Romero

  • Cath Muir

    Cath Muir
    Cath

  • Duncan Bayly , MND Australia

    Duncan Bayly , MND Australia

  • Mark Miller

    Mark Miller

  • Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

    Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

  • Brigitte Wernli,  Association ALS Switzerland,  Diagnosed 2014

    Brigitte Wernli, Association ALS Switzerland, Diagnosed 2014

  • Jo Knowlton and her dog, Scotland

    Jo Knowlton and her dog, Scotland

  • Cassio Fernando da Silva, Diagnosed 2013 , ABrELA, Brazil

    Cassio Fernando da Silva, Diagnosed 2013 , ABrELA, Brazil

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Irene McCaughey, Diagnosed 2011,  MND Australia

    Irene McCaughey, Diagnosed 2011, MND Australia

  • John Dinon, MND Australia

    John Dinon, MND Australia

  • Anita Forte, Les Turner ALS Foundation, USA

    Anita Forte, Les Turner ALS Foundation, USA

  • Marcelo Farinelli, Diagnosed 2006, ABrELA, Brazil

    Marcelo Farinelli, Diagnosed 2006, ABrELA, Brazil

  • Yolanda Armendariz, Diagnosed 2017 , FYADENMAC, Mexico

    Yolanda Armendariz, Diagnosed 2017 , FYADENMAC, Mexico

  • Zabun Nassar, MND Association, Diagnosed 2016, England

    Zabun Nassar, MND Association, Diagnosed 2016, England

  • Chih Ching Darren Wong, MND Malaysia

    Chih Ching Darren Wong, MND Malaysia

  • Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

    Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

  • Andrietta

    Andrietta

  • Purningam Jacob, Diagnosed 2012 , Asha Ek Hope Foundation, India

    Purningam Jacob, Diagnosed 2012 , Asha Ek Hope Foundation, India

  • Nicholas (Nic) Bowman, MND Association of South Africa,  Diagnosed 2016,  Australia

    Nicholas (Nic) Bowman, MND Association of South Africa, Diagnosed 2016, Australia

  • Susan Anderson, Diagnosed 2014 , Hope Loves Company,  USA

    Susan Anderson, Diagnosed 2014 , Hope Loves Company, USA

  • Willi Klein

    Willi Klein

  • Kirsten Harley,  Diagnosed 2013,  Australia

    Kirsten Harley, Diagnosed 2013, Australia

  • Roy

    Roy
    roy

  • Liong Ting Ngu, MND Malaysia, Diagnosed 2014

    Liong Ting Ngu, MND Malaysia, Diagnosed 2014

  • Jon Newsome, Les Turner ALS Foundation, USA

    Jon Newsome, Les Turner ALS Foundation, USA

  • Enzo Maccarrone, AISLA ONLUS, Italy

    Enzo Maccarrone, AISLA ONLUS, Italy

  • Dad

    Dad

  • Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

    Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

  • Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

    Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

  • Claudia Cominetti, Associazione conSLAncio Onlus,  Italy

    Claudia Cominetti, Associazione conSLAncio Onlus, Italy

  • Bayley, Australia

    Bayley, Australia

  • Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

    Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

  • Camilla Heiberg Freiberg, Muskelsvindfonden, Denmark

    Camilla Heiberg Freiberg, Muskelsvindfonden, Denmark

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • JP

    JP

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login